The Biology of Breast Cancer

  • Julie A. Guidroz
  • Ronald J. Weigel


Understanding the biology of breast cancer has provided important insights into the refinement of prognosis and novel treatment options in breast cancer. Recent developments in the molecular characterizations of breast tumors have advanced our understanding of breast oncogenesis and progression. This chapter will review the most relevant discoveries in breast cancer biology that have important clinical implications. Having a firm understanding of the biology of breast cancer is essential to understanding the molecular diagnostic tools and personalized treatment options that are becoming part of mainstream breast cancer care.


Breast Cancer Recurrence Score Atypical Ductal Hyperplasia HER2 Positive Tumor Gonadal Dysgenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dontu G. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2005;1(3):207.PubMedCrossRefGoogle Scholar
  2. 2.
    Dontu G. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004;15(5):193.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson E. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia. 2004;9(1):3.PubMedCrossRefGoogle Scholar
  4. 4.
    Walker RA. The aged breast. J Pathol. 2007;211(2):232.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson E. The role of estrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4(5):197.PubMedCrossRefGoogle Scholar
  6. 6.
    Heldring N. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905.PubMedCrossRefGoogle Scholar
  7. 7.
    Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469.PubMedCrossRefGoogle Scholar
  8. 8.
    Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319(1):1.PubMedCrossRefGoogle Scholar
  9. 9.
    Yuste L. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res. 2005;65(15):6801.PubMedCrossRefGoogle Scholar
  10. 10.
    Shackney SE. Molecular evolutionary patterns in breast cancer. Adv Anat Pathol. 2003;10(5):278.PubMedCrossRefGoogle Scholar
  11. 11.
    Allred DC. Histological and biological evolution of human premalignant breast disease. Endocri Relat Cancer. 2001;8(1):47.CrossRefGoogle Scholar
  12. 12.
    Wiechmann L. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008;112(10):2130.PubMedCrossRefGoogle Scholar
  13. 13.
    Nguyen PL. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373.PubMedCrossRefGoogle Scholar
  14. 14.
    Sørlie T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869.PubMedCrossRefGoogle Scholar
  15. 15.
    Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667.PubMedCrossRefGoogle Scholar
  16. 16.
    Turner BC. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res. 1998;58(23):5466.PubMedGoogle Scholar
  17. 17.
    Pellikainen JM. Activator protein-2 in carcinogenesis with a special reference to breast cancer–a mini review. Int J Cancer. 2007;120(10):2061.PubMedCrossRefGoogle Scholar
  18. 18.
    McPherson LA. AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res. 1999;27(20):4040.PubMedCrossRefGoogle Scholar
  19. 19.
    Jäger R. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res. 2003;1(12):921.PubMedGoogle Scholar
  20. 20.
    Fang S, Chen Y, Weigel R. GATA-3 as a marker of hormone response in breast cancer. J Surg Res. 2009;157:290–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Lowry JA. Molecular evolution of the GATA family of transcription factors: conservation within the DNA-binding domain. J Mol Evol. 2000;50(2):103.PubMedGoogle Scholar
  22. 22.
    Patient RK. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev. 2002;12(4):416.PubMedCrossRefGoogle Scholar
  23. 23.
    Hoch R. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999;84(2):122.PubMedCrossRefGoogle Scholar
  24. 24.
    Voduc D. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev. 2008;17(2):365.PubMedCrossRefGoogle Scholar
  25. 25.
    Jordan VC. Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci. 1988;26(2):97.PubMedCrossRefGoogle Scholar
  26. 26.
    Parikh P. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg. 2005;200(5):705.PubMedCrossRefGoogle Scholar
  27. 27.
    Cronin M. Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53(6):1084.PubMedCrossRefGoogle Scholar
  28. 28.
    Conlin AK. Use of the oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Mol Diagn Ther. 2007;11(6):355.PubMedCrossRefGoogle Scholar
  29. 29.
    Antoniou A. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117.PubMedCrossRefGoogle Scholar
  30. 30.
    Bonadona V. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer. 2005;43(4):404.PubMedCrossRefGoogle Scholar
  31. 31.
    Lynch HT. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 2008;14(1):3.PubMedCrossRefGoogle Scholar
  32. 32.
    Melchor L. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene. 2008;27(22):3165.PubMedCrossRefGoogle Scholar
  33. 33.
    Al-Hajj M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983.PubMedCrossRefGoogle Scholar
  34. 34.
    Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Fu J. Transcriptomic signatures in breast cancer. Mol Biosyst. 2007;3(7):466.PubMedCrossRefGoogle Scholar
  36. 36.
    Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117(11):3155.PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Iowa Hospitals and ClinicIowa CityUSA

Personalised recommendations